XENE (Xenon Pharmaceuticals) Other Financing: $5.49 Mil (TTM As of Mar. 2026)


XENE Xenon Pharmaceuticals Inc XENE
25 GF Score
Price $60.36
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Other Financing?

Xenon Pharmaceuticals XENE +0.38% 25 Other Financing is $5.49 Mil as of Mar. 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Xenon Pharmaceuticals's Other Financing for the three months ended in Mar. 2026 was $5.49 Mil.

Xenon Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $5.49 Mil.

Xenon Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals Other Financing Chart

Xenon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.71 0.04 0.05 4.96

Xenon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.49
XENE
25GF Score
Xenon Pharmaceuticals Inc XENE
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $5.49 Mil mean?
Xenon Pharmaceuticals (XENE) has a Other Financing of $5.49 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Xenon Pharmaceuticals and its competitors.
Is Xenon Pharmaceuticals' Other Financing too high?
Xenon Pharmaceuticals' current Other Financing is $5.49 Mil. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' Other Financing compare to DFTX and LEGN?
Xenon Pharmaceuticals' Other Financing of $5.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Xenon Pharmaceuticals and its competitors. Xenon Pharmaceuticals's current Other Financing is $5.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current Other Financing of $5.49 Mil. The current Other Financing is $5.49 Mil. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current Other Financing is $5.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xenon Pharmaceuticals Business Description

Other Exchanges XP0:Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score

Get the complete analysis for XENE

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.36
Price